Support teaching, research, and patient care.
Dr Thakor is adult and pediatric-certified Interventional Radiologist, and Physician-Scientist, who practices at Stanford University. He runs and directs a translational laboratory at Stanford University called Interventional Radiology Innovation at Stanford (IRIS). His vision is to develop the area of "Precision Delivery" in which targeted delivery approaches are used to locally deliver drug, gene, cell and cell-free therapies directly to organs using image-guided endovascular (i.e. within blood vessels), percutaneous (i.e. through the skin), endoluminal (i.e. within the bowel, respiratory or urinary system), and even using device implantation (i.e. bioscaffolds) approaches. His work focuses on using Precision Delivery strategies to ensure mesenchymal stem cells (MSCs), and their extracellular vesicles (EVs), can be delivered directly to target tissues or are coupled directly with target cells using novel bioscaffolds. His team works on the pancreas (for diabetes), kidney (for acute kidney injury), brain (for neurodegenerative conditions), lungs (for acute respiratory distress syndrome) and skin (for wound healing). They have also been investigating the use of focused ultrasound to modulate the microenvironment of injured tissues for stem cell homing and stimulating intrinsic tissue regeneration. In other work, his team are investigating the intrinsic molecular and regenerative signatures of mesenchymal stem cell therapies using genomic and proteomic profiling, and how these can be changed using focused ultrasound priming approaches. As a physician-scientist, Dr Thakor also makes sure that these innovations (i.e. technologies, therapies and devices) are effectively translated from the benchtop to the beside and to that effect, he is a PI and Co-I on several clinical trials.CLINICAL FOCUS:Interventional Radiology - Pediatric and AdultMedical DevicesACADEMIC FOCUS:Precision DeliveryFocused UltrasoundCell TherapyMesenchymal stem cells and their derived extracellular vesiclesBioscaffoldsMicroenvironment Modulation SUBJECT FOCUS:Pancreas Regeneration and Islet TransplantationKidney RegenerationBrain RegenerationLiver RegenerationSkin RegenerationSolid Organ Tumorshttps://www.stanfordiris.com/
Dr. Thakor is a Physician Scientist at Stanford University. He is dual fellowship trained in both pediatric and adult Interventional Radiology, and holds a joint appointment as an attending Interventional Radiologist at Lucile Packard Children’s Hospital and Stanford University Medical Center. His clinical interests are in pediatric Interventional Radiology, islet transplantation and focused ultrasound therapy. Dr. Thakor is an Attending Interventional Radiologist who runs his own translational laboratory at Stanford University investigating the use of mesenchymal stem cells (MSCs) based therapies (which includes both the parent cell and their extra-cellular vesicles (EVs)), for multiple disease states given their anti-inflammatory, pro-angiogenic and immunomodulatory properties. In particular, Dr. Thakor’s team has been focusing on islet transplantation, pancreas, kidney, lung, skin and neuronal regeneration.His work focuses on: (i) understanding the genomic and proteomic profiles of different sources of MSCs and their derived EVs, (ii) developing novel Precision Delivery strategies to deliver and home these MSC-based therapies to target tissues, (iii) using focused ultrasound to optimize the injured tissue microenvironment for these therapies and then (iv) imaging the biodistribution of MSCs with novel imaging probes. By translating stem cell therapies into patients using minimally invasive strategies, his team is leading the efforts in a new emerging field called “Interventional Regenerative Medicine (IRM)”. In addition, his team has been developing multi-functional bioscaffolds and nanoplatforms to facilitate the clinical translation of different cellular therapies.
High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)
This study will examine whether delivery of high dose steroids, directly into the inflamed
bowel via its arterial blood supply, will be better for treating uncontrolled flares of
inflammatory bowel disease in patients compared to conventional intra-venous or oral
administration of this drug. Patients aged 4-25 years of age will be recruited.
In this study, we hope to also learn how this directed steroid delivery during an active
flare will improve patient symptoms as well as the appearance of inflamed segments of bowel
determined by imaging or biopsy (i.e. at the time of endoscopy). Additional data will
determine how the blood vessels in the bowel affect, and potentially even drive the
mechanisms, of inflammatory bowel disease.
View full details